Guangzhou Sinogen Pharmaceutical has been granted with 2022 Top 100 Chinese Pharmaceutical Innovative Seed Enterprise.

Recently, the world's leading life science professional information service provider and database "Clarivate" and the well-known medical media "E Medicine Manager" has selected the second "Top 100 Chinese Pharmaceutical Innovation Seed Enterprises" after four months of data screening, integration and analysis. Sinogen is ranked on the list with its leading platform advantage in the field of bacterial carrier genetic engineering medicine research and development and production, as well as the achievements in their intellectual property system and the promotion of clinical pipelines. 

Based on Derwent's patent data and Cortellis's competitive intelligence and clinical trial data, this selection selects the most representative, growing and innovative 100 Chinese pharmaceutical enterprises from more than 5000 Chinese pharmaceutical enterprises from the three dimensions of "innovation foundation, innovation process and innovation achievements", with "the number of authorized patents and total patent applications, the number of products under clinical trials , and the number of new medicines approved" as the main evaluation indicator. These pharmaceutical enterprises mostly have not been established for a long time and have not been publicly listed on stock market, but they have unique innovative products or technologies and have become a strong backup force for China's pharmaceutical innovation.

This selection focuses on the transformation and upgrading of China's pharmaceutical industry. While discovering the potential of industrial innovation and investigating the core competitiveness of enterprises, it also aims to more comprehensively and truly reflect the current situation and future of China's pharmaceutical innovation, and provide a model for the industry to grow healthily.

Attached: The complete list of "China's Top 100 Pharmaceutical Innovation Seed Companies 2022"